General Information of Drug Off-Target (DOT) (ID: OT2ZSZ6P)

DOT Name Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1)
Synonyms
EC 2.4.1.122; B3Gal-T8; Core 1 O-glycan T-synthase; Core 1 UDP-galactose:N-acetylgalactosamine-alpha-R beta 1,3-galactosyltransferase 1; Beta-1,3-galactosyltransferase; Core 1 beta1,3-galactosyltransferase 1; C1GalT1; Core 1 beta3-Gal-T1
Gene Name C1GALT1
Related Disease
Adenocarcinoma ( )
Breast cancer ( )
Breast carcinoma ( )
Carcinoma ( )
Carcinoma of esophagus ( )
Cardiovascular disease ( )
Castration-resistant prostate carcinoma ( )
Colon cancer ( )
Colon carcinoma ( )
Colorectal carcinoma ( )
Epithelial ovarian cancer ( )
Esophageal cancer ( )
Esophageal squamous cell carcinoma ( )
Head and neck cancer ( )
Head and neck carcinoma ( )
Head-neck squamous cell carcinoma ( )
Hepatocellular carcinoma ( )
Matthew-Wood syndrome ( )
Neoplasm ( )
Neoplasm of esophagus ( )
Nephropathy ( )
Non-insulin dependent diabetes ( )
Ovarian cancer ( )
Ovarian neoplasm ( )
Prostate cancer ( )
Prostate carcinoma ( )
Thrombocytopenia ( )
Vascular purpura ( )
Advanced cancer ( )
Chronic obstructive pulmonary disease ( )
UniProt ID
C1GLT_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
2.4.1.122
Pfam ID
PF02434
Sequence
MASKSWLNFLTFLCGSAIGFLLCSQLFSILLGEKVDTQPNVLHNDPHARHSDDNGQNHLE
GQMNFNADSSQHKDENTDIAENLYQKVRILCWVMTGPQNLEKKAKHVKATWAQRCNKVLF
MSSEENKDFPAVGLKTKEGRDQLYWKTIKAFQYVHEHYLEDADWFLKADDDTYVILDNLR
WLLSKYDPEEPIYFGRRFKPYVKQGYMSGGAGYVLSKEALKRFVDAFKTDKCTHSSSIED
LALGRCMEIMNVEAGDSRDTIGKETFHPFVPEHHLIKGYLPRTFWYWNYNYYPPVEGPGC
CSDLAVSFHYVDSTTMYELEYLVYHLRPYGYLYRYQPTLPERILKEISQANKNEDTKVKL
GNP
Function
Glycosyltransferase that generates the core 1 O-glycan Gal-beta1-3GalNAc-alpha1-Ser/Thr (T antigen), which is a precursor for many extended O-glycans in glycoproteins. Plays a central role in many processes, such as angiogenesis, thrombopoiesis and kidney homeostasis development.
Tissue Specificity Widely expressed. Highly expressed in kidney, heart, placenta and liver.
KEGG Pathway
Mucin type O-glycan biosynthesis (hsa00512 )
Other types of O-glycan biosynthesis (hsa00514 )
Metabolic pathways (hsa01100 )
Reactome Pathway
O-linked glycosylation of mucins (R-HSA-913709 )
Defective C1GALT1C1 causes TNPS (R-HSA-5083632 )
BioCyc Pathway
MetaCyc:HS02901-MONOMER

Molecular Interaction Atlas (MIA) of This DOT

30 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Adenocarcinoma DIS3IHTY Strong Biomarker [1]
Breast cancer DIS7DPX1 Strong Biomarker [2]
Breast carcinoma DIS2UE88 Strong Biomarker [2]
Carcinoma DISH9F1N Strong Biomarker [3]
Carcinoma of esophagus DISS6G4D Strong Biomarker [4]
Cardiovascular disease DIS2IQDX Strong Genetic Variation [5]
Castration-resistant prostate carcinoma DISVGAE6 Strong Biomarker [6]
Colon cancer DISVC52G Strong Altered Expression [7]
Colon carcinoma DISJYKUO Strong Altered Expression [7]
Colorectal carcinoma DIS5PYL0 Strong Biomarker [8]
Epithelial ovarian cancer DIS56MH2 Strong Biomarker [9]
Esophageal cancer DISGB2VN Strong Biomarker [4]
Esophageal squamous cell carcinoma DIS5N2GV Strong Biomarker [10]
Head and neck cancer DISBPSQZ Strong Biomarker [11]
Head and neck carcinoma DISOU1DS Strong Biomarker [11]
Head-neck squamous cell carcinoma DISF7P24 Strong Altered Expression [11]
Hepatocellular carcinoma DIS0J828 Strong Biomarker [12]
Matthew-Wood syndrome DISA7HR7 Strong Altered Expression [13]
Neoplasm DISZKGEW Strong Altered Expression [14]
Neoplasm of esophagus DISOLKAQ Strong Biomarker [4]
Nephropathy DISXWP4P Strong Biomarker [15]
Non-insulin dependent diabetes DISK1O5Z Strong Genetic Variation [5]
Ovarian cancer DISZJHAP Strong Biomarker [9]
Ovarian neoplasm DISEAFTY Strong Biomarker [9]
Prostate cancer DISF190Y Strong Biomarker [6]
Prostate carcinoma DISMJPLE Strong Biomarker [6]
Thrombocytopenia DISU61YW Strong Biomarker [15]
Vascular purpura DIS6ZZMF Strong Genetic Variation [16]
Advanced cancer DISAT1Z9 moderate Altered Expression [11]
Chronic obstructive pulmonary disease DISQCIRF Limited Genetic Variation [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 30 Disease(s)
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
12 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate increases the expression of Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1). [18]
Tretinoin DM49DUI Approved Tretinoin increases the expression of Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1). [19]
Acetaminophen DMUIE76 Approved Acetaminophen increases the expression of Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1). [20]
Ivermectin DMDBX5F Approved Ivermectin decreases the expression of Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1). [21]
Quercetin DM3NC4M Approved Quercetin decreases the expression of Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1). [22]
Temozolomide DMKECZD Approved Temozolomide increases the expression of Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1). [23]
Testosterone DM7HUNW Approved Testosterone decreases the expression of Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1). [24]
Panobinostat DM58WKG Approved Panobinostat increases the expression of Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1). [25]
Demecolcine DMCZQGK Approved Demecolcine decreases the expression of Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1). [26]
PMID28460551-Compound-2 DM4DOUB Patented PMID28460551-Compound-2 increases the expression of Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1). [28]
Trichostatin A DM9C8NX Investigative Trichostatin A increases the expression of Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1). [29]
Milchsaure DM462BT Investigative Milchsaure increases the expression of Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1). [30]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 Drug(s)
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene decreases the methylation of Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1). [27]
------------------------------------------------------------------------------------

References

1 Core 1-derived mucin-type O-glycosylation protects against spontaneous gastritis and gastric cancer.J Exp Med. 2020 Jan 6;217(1):e20182325. doi: 10.1084/jem.20182325.
2 Up-regulation of C1GALT1 promotes breast cancer cell growth through MUC1-C signaling pathway.Oncotarget. 2015 Mar 20;6(8):6123-35. doi: 10.18632/oncotarget.3045.
3 Relevance of Gal-GalNAc-containing glycans and the enzymes involved in their synthesis for invasion and survival in breast cancer patients.Breast Cancer Res Treat. 2015 Jun;151(3):515-28. doi: 10.1007/s10549-015-3425-0. Epub 2015 May 15.
4 Knockdown of C1GalT1 inhibits radioresistance of human esophageal cancer cells through modifying 1-integrin glycosylation.J Cancer. 2018 Jun 23;9(15):2666-2677. doi: 10.7150/jca.25252. eCollection 2018.
5 Leveraging Polygenic Functional Enrichment to Improve GWAS Power.Am J Hum Genet. 2019 Jan 3;104(1):65-75. doi: 10.1016/j.ajhg.2018.11.008. Epub 2018 Dec 27.
6 O-Glycosylation-mediated signaling circuit drives metastatic castration-resistant prostate cancer.FASEB J. 2018 Jun 15:fj201800687. doi: 10.1096/fj.201800687. Online ahead of print.
7 Suppression of core 1 Gal-transferase is associated with reduction of TF and reciprocal increase of Tn, sialyl-Tn and Core 3 glycans in human colon cancer cells.PLoS One. 2013;8(3):e59792. doi: 10.1371/journal.pone.0059792. Epub 2013 Mar 25.
8 T-Synthase Deficiency Enhances Oncogenic Features in Human Colorectal Cancer Cells via Activation of Epithelial-Mesenchymal Transition.Biomed Res Int. 2018 Jun 21;2018:9532389. doi: 10.1155/2018/9532389. eCollection 2018.
9 C1GALT1 Seems to Promote In Vitro Disease Progression in Ovarian Cancer.Int J Gynecol Cancer. 2017 Jun;27(5):863-871. doi: 10.1097/IGC.0000000000000965.
10 Clinic implication of MUC1 O-glycosylation and C1GALT1 in esophagus squamous cell carcinoma.Sci China Life Sci. 2018 Nov;61(11):1389-1395. doi: 10.1007/s11427-017-9345-7. Epub 2018 Aug 1.
11 C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer.Oncogene. 2018 Oct;37(43):5780-5793. doi: 10.1038/s41388-018-0375-0. Epub 2018 Jun 21.
12 C1GALT1 promotes invasive phenotypes of hepatocellular carcinoma cells by modulating integrin 1 glycosylation and activity.PLoS One. 2014 Aug 4;9(8):e94995. doi: 10.1371/journal.pone.0094995. eCollection 2014.
13 A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer.J Pharmacol Exp Ther. 2019 Sep;370(3):894-901. doi: 10.1124/jpet.118.255372. Epub 2019 Jan 25.
14 Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers.BMC Cancer. 2018 Aug 16;18(1):827. doi: 10.1186/s12885-018-4708-8.
15 Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene.Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16442-7. doi: 10.1073/pnas.0607872103. Epub 2006 Oct 24.
16 A study on the association between C1GALT1 polymorphisms and the risk of Henoch-Schnlein purpura in a Chinese population.Rheumatol Int. 2013 Oct;33(10):2539-42. doi: 10.1007/s00296-013-2761-9. Epub 2013 Apr 27.
17 Genetic overlap of chronic obstructive pulmonary disease and cardiovascular disease-related traits: a large-scale genome-wide cross-trait analysis.Respir Res. 2019 Apr 2;20(1):64. doi: 10.1186/s12931-019-1036-8.
18 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
19 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
20 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
21 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
22 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
23 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
24 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
25 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
26 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
27 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
28 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
29 From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
30 Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.